Provided by Tiger Trade Technology Pte. Ltd.

Sionna Therapeutics

6.46
+0.43007.13%
Post-market: 6.36-0.0964-1.49%19:09 EDT
Volume:1.41M
Turnover:8.89M
Market Cap:290.69M
PE:-2.98
High:6.48
Open:5.95
Low:5.93
Close:6.03
52wk High:54.97
52wk Low:4.01
Shares:45.00M
Float Shares:16.73M
Volume Ratio:1.21
T/O Rate:8.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1683
EPS(LYR):-1.8835
ROE:-32.34%
ROA:-21.54%
PB:1.09
PE(LYR):-3.43

Loading ...

Press Release: Sionna Therapeutics Reports First Quarter 2026 Financial Results

Dow Jones
·
May 12

Sionna Therapeutics director Peter A. Thompson sells 292,952 shares for $13.37 million

Reuters
·
May 12

OrbiMed Advisors disposes 292,952 Sionna Therapeutics shares for $13.5 million

Reuters
·
May 12

Sionna Therapeutics Initiated at Outperform by Wedbush

Dow Jones
·
May 05

Sionna Therapeutics Inc : Wedbush Initiates Coverage With Outperform Rating; Target Price $53

THOMSON REUTERS
·
May 05

Wedbush Initiates Sionna Therapeutics at Outperform With $53 Price Target

MT Newswires Live
·
May 05

Is Sionna Therapeutics (SION) Stock Overvalued After Its Strong 1 Year Run And 6x P/B Multiple

Simply Wall St.
·
May 05

Sionna Therapeutics initiated with an Outperform at Wedbush

TIPRANKS
·
May 05

Sionna Therapeutics Is Maintained at Buy by Jones Trading

Dow Jones
·
Apr 29

Sionna Therapeutics price target raised to $63 from $52 at JonesResearch

TIPRANKS
·
Apr 28

Sionna Therapeutics announces annual shareholder meeting

Reuters
·
Apr 28

Sionna Therapeutics Price Target Maintained With a $58.00/Share by BTIG

Dow Jones
·
Apr 28

Sionna Therapeutics completes enrollment in Phase 2a PreciSION CF trial of SION-719

Reuters
·
Apr 27

Sionna Therapeutics Inc: Anticipates Data From Precision CF Trial in Summer of 2026.

THOMSON REUTERS
·
Apr 27

Sionna Therapeutics Completes Enrollment in Precision CF Phase 2a Trial Evaluating Nbd1 Stabilizer, Sion-719, Added to Standard of Care in Participants With Cystic Fibrosis

THOMSON REUTERS
·
Apr 27

Sionna director Peter A. Thompson disposes of USD 2.5 million common shares

Reuters
·
Apr 22

OrbiMed Advisors reports Sionna Therapeutics common stock disposal worth $2.5 million

Reuters
·
Apr 22

Sionna director Peter A. Thompson disposes of common shares worth $23.2 million

Reuters
·
Apr 17

OrbiMed Advisors reports Sionna Therapeutics common stock disposal worth $23.1 million

Reuters
·
Apr 17

Assessing Sionna Therapeutics (SION) Valuation After Recent Trading And Cystic Fibrosis Pipeline Expectations

Simply Wall St.
·
Apr 10